Scholarlink

Introduction <p>Guselkumab, a selective p19 subunit-targeted IL-23 inhibitor, has shown high efficacy and a favorable safety profile in clinical trials of moderate-to-severe plaque psoriasis (PsO). However, real-world data on patient satisfaction with the guselkumab One-Press device, particularly in Portuguese clinical practice, are limited.</p> Methods <p>This real-world, prospective, multicenter, nationwide study evaluated patient satisfaction with self-administration of guselkumab using the One-Press device over 52&#xa0;weeks in adults with moderate-to-severe plaque PsO. A total of 101 patients from 10 dermatology centers were enrolled between September 2022 and November 2023. Patient satisfaction was assessed using the Self-Injection Assessment Questionnaire (SIAQ) at baseline and week 20. Using the SIAQ, patients rated the One-Press device’s acceptability across six domains predose and postdose (feeling about injections, self-confidence, and satisfaction with self-injection; postdose only: self-image, pain and skin reactions during or after the injection, and ease of self-injection device use). Quality of life (Dermatology Life Quality Index [DLQI]), clinical effectiveness (Investigator Global Assessment [IGA]), and safety were evaluated through week 52.</p> Results <p>Mean SIAQ PRE Module score increased significantly from 6.9 ± 1.8 at baseline to 8.3 ± 1.5 at week 20 (<i>p</i> &lt; 0.001), indicating improved self-injection experience. Injection-related anxiety decreased from 63.4% to 48.9%. Mean DLQI score improved from 8.5 ± 6.9 at baseline to 1.5 ± 2.8 at week 20 and 1.1 ± 3.0 at week 52; 70.8% of patients achieved DLQI 0/1 by week 52. Despite nearly 90% having prior biologic or systemic therapy exposure, IGA 0/1 (“clear” or “almost clear”) was achieved by 86.3% of patients at week 20 and 91.0% at week 52. A total of 198 adverse events (AEs) were reported in 62.4% of patients and were mainly mild, localized injection-site reactions. One serious AE was considered related to guselkumab.</p> Conclusions <p>In routine clinical practice in Portugal, guselkumab self-administered using the One-Press device demonstrated high patient satisfaction, substantial quality-of-life improvement, robust clinical effectiveness, and a favorable safety profile. These real-world findings support the usability and benefit-risk profile of self-administered guselkumab for patients with moderate-to-severe plaque PsO.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Tiago Torres,
  • João Teles Sousa,
  • Joana Antunes,
  • Pedro Mendes-Bastos,
  • Ana Brasileiro,
  • Vítor Neto,
  • Martinha Henrique,
  • Rita Pimenta,
  • Sofia Magina,
  • Diana Lourenço,
  • Fernando Mota

摘要

Introduction

Guselkumab, a selective p19 subunit-targeted IL-23 inhibitor, has shown high efficacy and a favorable safety profile in clinical trials of moderate-to-severe plaque psoriasis (PsO). However, real-world data on patient satisfaction with the guselkumab One-Press device, particularly in Portuguese clinical practice, are limited.

Methods

This real-world, prospective, multicenter, nationwide study evaluated patient satisfaction with self-administration of guselkumab using the One-Press device over 52 weeks in adults with moderate-to-severe plaque PsO. A total of 101 patients from 10 dermatology centers were enrolled between September 2022 and November 2023. Patient satisfaction was assessed using the Self-Injection Assessment Questionnaire (SIAQ) at baseline and week 20. Using the SIAQ, patients rated the One-Press device’s acceptability across six domains predose and postdose (feeling about injections, self-confidence, and satisfaction with self-injection; postdose only: self-image, pain and skin reactions during or after the injection, and ease of self-injection device use). Quality of life (Dermatology Life Quality Index [DLQI]), clinical effectiveness (Investigator Global Assessment [IGA]), and safety were evaluated through week 52.

Results

Mean SIAQ PRE Module score increased significantly from 6.9 ± 1.8 at baseline to 8.3 ± 1.5 at week 20 (p < 0.001), indicating improved self-injection experience. Injection-related anxiety decreased from 63.4% to 48.9%. Mean DLQI score improved from 8.5 ± 6.9 at baseline to 1.5 ± 2.8 at week 20 and 1.1 ± 3.0 at week 52; 70.8% of patients achieved DLQI 0/1 by week 52. Despite nearly 90% having prior biologic or systemic therapy exposure, IGA 0/1 (“clear” or “almost clear”) was achieved by 86.3% of patients at week 20 and 91.0% at week 52. A total of 198 adverse events (AEs) were reported in 62.4% of patients and were mainly mild, localized injection-site reactions. One serious AE was considered related to guselkumab.

Conclusions

In routine clinical practice in Portugal, guselkumab self-administered using the One-Press device demonstrated high patient satisfaction, substantial quality-of-life improvement, robust clinical effectiveness, and a favorable safety profile. These real-world findings support the usability and benefit-risk profile of self-administered guselkumab for patients with moderate-to-severe plaque PsO.